非小细胞肺癌辅助化疗的真实世界疗效与毒性：单中心经验
Real-world outcomes and toxicity of adjuvant chemotherapy in NSCLC: a single-center experience.
作者信息
Cronin Christopher, Iqbal Shahid, Farooq Abdul R, O'Dea Pauline, Burke Louise, O'Reilly Seamus, O'Mahony Deirdre, Power Derek G, Bambury Richard M, Collins Dearbhaile C
机构信息
Department of Medical Oncology, Cork University Hospital, Wilton, Co Cork, T12 EC8P, Ireland.
Department of Pathology, Cork University Hospital, Wilton, Co Cork, T12 EC8P, Ireland.
出版信息
Lung Cancer Manag. 2023 Apr 3;12(1):LMT58. doi: 10.2217/lmt-2022-0014. eCollection 2023 Mar.
AIM
Adjuvant chemotherapy in NSCLC is associated with modest benefits and significant toxicity. We sought to evaluate the toxicity of adjuvant chemotherapy and disease-specific outcomes in a real-world population.
METHODS
We performed a retrospective analysis of patients undergoing adjuvant chemotherapy for NSCLC in an Irish center over a 7-year period. We described treatment-associated toxicity, recurrence-free survival and overall survival.
RESULTS
62 patients underwent adjuvant chemotherapy. Treatment-associated hospitalisation occurred in 29% of patients. Relapse was recorded in 56% of patients and median recurrence-free survival was 27 months.
CONCLUSION
High rates of disease recurrence and treatment-associated morbidity were observed in patients receiving adjuvant chemotherapy for NSCLC. Novel therapeutic strategies are required to improve outcomes in this population.
目的
非小细胞肺癌（NSCLC）的辅助化疗疗效有限且毒性显著。我们试图评估在实际临床人群中辅助化疗的毒性及疾病特异性转归。
方法
我们对爱尔兰一家中心7年间接受NSCLC辅助化疗的患者进行了回顾性分析。我们描述了与治疗相关的毒性反应、无复发生存期和总生存期。
结果
62例患者接受了辅助化疗。29%的患者出现了与治疗相关的住院情况。56%的患者出现复发，无复发生存期的中位数为27个月。
结论
接受NSCLC辅助化疗的患者疾病复发率和治疗相关发病率较高。需要新的治疗策略来改善该人群的治疗效果。
Zotero 插件